Continuing Education Activity
Ethacrynic acid is a medication used in the management and treatment of chronic heart failure. It is in the loop diuretic class of drugs. This activity describes the indications, action, and contraindications for ethacrynic acid as a valuable agent in managing fluid overload and CHF. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with CHF and related conditions.
- Explain the treatment considerations for patients with chronic heart failure and a sulfa allergy.
- Describe the adverse effects and contraindications of ethacrynic acid.
- Review the appropriate monitoring for patients on ethacrynic acid therapy.
- Outline some interprofessional team strategies for improving care coordination and communication to advance ethacrynic acid and improve outcomes.
Ethacrynic acid is a loop diuretic that gained FDA approval for widespread use in 1967. Unlike other loop diuretics, ethacrynic acid is a novel drug due to the absence of a sulfonamide group in its structure, allowing its use in critically ill patients with life-threatening sulfa-allergies. In adults, ethacrynic acid is a choice for the relief of edema in patients with renal failure, congestive heart failure, and cirrhotic ascites in the setting of sulfonamide hypersensitivity and treatment-resistant pathologies. The FDA also approves its use in the management of ascites due to malignancy, lymphedema, and idiopathic edema. If rapid onset diuresis is the desired goal, the FDA allows ethacrynic acid to be used to manage flash pulmonary edema or hospitalized pediatrics over 1-year-old with congenital heart failure. Ethacrynic acid is preferable for both these groups due to its greater urinary output and fluid balance than furosemide. Non-FDA-approved uses include hypertension, uremia, and metabolic acidosis.
Ethacrynic acid is also indicated during diuretic renal scintigraphy in patients with sulfonamide allergies. Previously, diagnosing renal obstruction in this patient group was limited to two options: 1) using furosemide regardless of hypersensitivity because, in most cases, allergic reactions are practically mild or 2) resorting to the less accurate non-diuretic route for patients with known severe reactions to sulfa drugs. An article from the Journal of Nuclear Medicine discusses how this dilemma led to ethacrynic acid replacing furosemide during diuretic renal scintigraphy. In looking for an alternative to furosemide, researchers discovered that many loop diuretics, including thiazides and carbonic anhydrase inhibitors, are composed of sulfonamide moieties. Because of this, in addition to intravenous ethacrynic acid's nearly 100 percent bioavailability and rapid onset of action, it has become a favorable option for these patients.
In recent research, ethacrynic acid may be useful as adjuvant anticancer therapy. Glutathione transferase is often overexpressed in tumor cells, conferring resistance to many antineoplastic regimens. In vitro studies have showcased ethacrynic acid's ability to inhibit glutathione transferase. Clinical trials for its efficacy as an adjuvant for multiple myeloma have also shown promise.
Mechanism of Action
The main site of action is limited to the ascending limb of the nephron’s loop of Henle, which is responsible for sodium and chloride reabsorption. Normally, the ascending loop of Henle reabsorbs 25% to 30% of the tubular fluid’s sodium while remaining relatively impermeable to water (except in the presence of antidiuretic hormone, which allows water reabsorption through aquaporin channels). By inhibiting active sodium transport via inhibition of the Na-K-2Cl symporter, ethacrynic acid prevents the kidney from forming hypotonic urine. These ions retained in tubular fluid create an electrochemical gradient that prevents reabsorption of calcium and magnesium as well. In turn, this increases the osmotic force inside the renal tubule and prevents water from leaking into the renal interstitium. As a result, ethacrynic acid leads to increased natriuresis and diuresis. Ethacrynic acid has also been demonstrated to cause venous dilation contributing to rapid pulmonary decongestion even before its onset of diuresis.
Intravenous application is the preferred agent in inpatient settings for the management of flash pulmonary edema and treatment-resistant forms of edema. Ethacrynic acid may be administered via IV at 0.5 to 1 mg/kg. Oral forms are also available at doses of 20 mg to 400 mg given one to four times daily, though typical doses are 50 to 200 mg daily. The onset of action of the oral form occurs with peak diuresis at about 2 to 4 hours, showing complete diuresis within 6 to 8 hours. However, the onset of action intravenously is approximately 5 minutes, with a peak of activity occurring at 30 minutes.
Since diuresis and natriuresis occur so rapidly using ethacrynic acid, reductions in blood volume lead to a decrease in mean arterial pressure. Reduced cardiac index and reflex tachycardia can also occur due to the sudden decrease in preload.  Within one use, intravenous ethacrynic acid can precipitate immediate volume depletion that can potentially be life-threatening. Because of this, close monitoring of blood pressure is advisable during use.
When diuresis is excessive, decreased renal blood flow and glomerular filtration rate result in severe azotemia and uremia. Orthostatic hypotension or even shock can ensue if large amounts of water and sodium are lost too quickly. With repeated uses of intravenous ethacrynic acid, hypokalemic metabolic acidosis and magnesium depletion can occur as a direct result of its action on the loop of Henle. Potassium losses can precipitate digoxin toxicity in heart failure patients as well as muscular weakness and intestinal atony.
Of note, the most novel adverse effect of ethacrynic acid is ototoxicity, which can be seen after only one use, especially when delivered intravenously. The stria vascularis is a secretory tissue of the lateral wall of the cochlear duct. Its function is to secrete endolymph while simultaneously maintaining its gradient of potassium ions to sodium ions, contributing to the resting endocochlear potential (EP). The positive EP usually rests at +90mV and is significantly reduced after a single injection of ethacrynic acid in animal models. This data suggests that the stria vascularis is a major target for ethacrynic acid. Further analysis discovered that the reduction in EP is due to decreased blood flow to the stria vascularis caused by ethacrynic acid’s activation of renin secreting cells in the cochlea. Similar to human cases, the damage replicated in animal models was only transient, recovering within hours of injection.
Transient hearing loss can be observed in patients after one-time use of intravenous ethacrynic acid and can occur as quickly as 15 minutes after administration. Transient hearing loss has also been observed after long-term oral use, particularly in patients with decreased renal function since the kidneys metabolize ethacrynic acid. When using ethacrynic acid in patients already treated with ototoxic drugs such as aminoglycosides or cisplatin, the side effects are synergistic; this can lead to permanent cochlear hair cell loss due to cochlear ischemia. Transient tinnitus, vertigo, and permanent hearing loss, including bilateral deafness, are significant consequences of ethacrynic acid, contraindicating its use in patients receiving treatment with other ototoxic drugs.
Gastrointestinal side effects are less common and include nausea, vomiting, diarrhea, and epigastric pain that are usually temporary. In a few rare cases, ethacrynic acid has been implicated in pancreatitis and hepatitis, though causality remains unclear. Further, similar to thiazides, because it is an organic acid and can compete with urea in the nephron, ethacrynic acid can cause an increase in serum uric acid, precipitating acute gout. Lastly, ethacrynic acid can cause hemolysis via inhibition of red cell ATPase and glycolytic enzymes in vitro, which becomes clinically relevant during the administration of blood products in the elderly. It is common practice to administer loop diuretics to elderly patients during blood product transfusion to avoid exacerbating symptoms of congestive heart failure. Hemolysis occurring with transfusion leads to an increase in the plasma concentration of ethacrynic acid, which could potentiate the adverse effects discussed above.
Ethacrynic acid is contraindicated in patients already receiving treatment with other ototoxic drugs such as cisplatin or gentamycin. When taken alone, ototoxic drugs like gentamycin have a relatively low uptake into the cochlea, explaining why they rarely cause hearing loss. However, when taken with high doses of ethacrynic acid, permanent hearing loss can be observed. This effect appears to be caused by ethacrynic acid's effect on cochlear tight junctions. Damage to these tight junctions leads to increased permeability and a weakened blood-cochlear barrier allowing entry of ototoxic drugs.
Ethacrynic acid is a rapid-acting loop diuretic. Onset can occur at 5 minutes with a peak onset of action within 30 minutes. Because it has 100% bioavailability, ethacrynic acid dosing is according to the weight of the patient. Intravenous doses usually range between 0.5 to 1mg/kg and typically do not exceed 100 mg in a single dose. Monitoring is similar to that of other loop diuretics. Since electrolyte abnormalities and volume depletion are of concern, kidney function, creatinine levels, basic electrolytes, and blood pressure are monitored early in the course of use.
Currently, there is no antidote described in the literature for the toxicity of ethacrynic acid. Toxicity usually occurs in elderly patients with diminished renal function leading to volume depletion and, in some cases, toxicity. When adverse side effects occur, rapid discontinuation of ethacrynic acid and supportive care can lead to the resolution of symptoms.
Enhancing Healthcare Team Outcomes
Ethacrynic acid is usually reserved for patients with sulfa allergies. The interprofessional healthcare team should be aware of the drug's rapid onset and monitor the dosages of the drug to avoid hypovolemia and electrolyte imbalances. Pharmacists and clinicians are to pay close attention to patients with renal failure and adjust therapeutic levels of ethacrynic acid accordingly. Nurses should be aware of the signs of adverse events so they can report these promptly to the ordering clinician. To improve outcomes, monitor blood pressure, and avoid concurrent use of other ototoxic medications. If ototoxicity, hepatotoxicity, or electrolyte imbalances are suspected, ethacrynic acid therapy should stop immediately, and the patient should receive appropriate supportive care and symptom management. Utilizing interprofessional team strategies will result in better therapeutic outcomes and fewer adverse events with ethacrynic acid, driving better patient outcomes. [Level 5]